| HOME >> BIOLOGY >> TECHNOLOGY |
Marketing and business
development 1,742 1,504 511 375
General and administrative 2,903 1,860 829 680
Operating loss 11,045 8,145 3,729 2,216
Financial expenses (income),
net 3,616 (538) 149 (200)
Net loss $ 14,661 $ 7,607 $ 3,878 $ 2,016
Basic and diluted net loss
per Ordinary share $ 1.32 $ 2.98 $ 0.33 $ 0.23
Weighted average number of
Ordinary shares used to
compute basic and diluted
net loss per Ordinary share 11,142,149 2,551,860 11,920,401 8,874,841
Contact: Media
Rachel Spielman
T: +1-212-583-2714
Investors
Ron Kamienchick
T: +1-646-509-1893
E: investors@rosettagenomics.com
------
Rosetta Genomics Reports First Quarter 2008 Financial Results
First Diagnostic Test Based on Company's microRNA Technology Submitted for Regulatory Approval to the New York State Department of Health by Columbia University Medical CenterAdditional West Coast Clinical Laboratory to Validate and Offer Tests Based on Rosetta Genomics' microRNA TechnologyTwo Additional microRNA-Related Patents Allowed
REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, May 21
/PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading
molecular diagnostics company, reported today its consolidated financial
results for the quarter ended March 31, 2008 and busin
'/>"/>
| SOURCE Rosetta Genomics Ltd Copyright©2008 PR Newswire. All rights reserved |